Geneva Capital Management LLC Has $46.66 Million Position in Vericel Co. (NASDAQ:VCEL)

Geneva Capital Management LLC grew its position in shares of Vericel Co. (NASDAQ:VCEL) by 61.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,104,386 shares of the biotechnology company’s stock after purchasing an additional 420,078 shares during the quarter. Geneva Capital Management LLC owned approximately 2.25% of Vericel worth $46,660,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in VCEL. International Assets Investment Management LLC boosted its position in Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after buying an additional 619 shares during the period. CWM LLC lifted its holdings in shares of Vericel by 319.0% during the second quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 504 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 405 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Vericel by 22.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 322 shares during the period. Finally, Nisa Investment Advisors LLC raised its position in Vericel by 9.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 220 shares during the last quarter.

Insider Buying and Selling

In other Vericel news, Director Steven C. Gilman sold 5,833 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total transaction of $235,361.55. Following the completion of the sale, the director now owns 11,000 shares in the company, valued at approximately $443,850. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the transaction, the chief executive officer now owns 220,937 shares in the company, valued at approximately $9,142,373.06. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steven C. Gilman sold 5,833 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total value of $235,361.55. Following the completion of the sale, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $443,850. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,166 shares of company stock worth $1,200,764 in the last ninety days. Corporate insiders own 5.20% of the company’s stock.

Analyst Upgrades and Downgrades

VCEL has been the topic of a number of analyst reports. Canaccord Genuity Group assumed coverage on Vericel in a research report on Friday, August 9th. They issued a “buy” rating and a $57.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Vericel in a research report on Friday, November 8th. Stephens increased their price objective on shares of Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Canaccord Genuity Group initiated coverage on shares of Vericel in a research note on Friday, August 9th. They set a “buy” rating and a $57.00 target price for the company. Finally, Truist Financial upped their price target on shares of Vericel from $56.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Vericel currently has an average rating of “Moderate Buy” and an average price target of $57.71.

Vericel Trading Down 1.6 %

VCEL opened at $55.89 on Wednesday. The company has a market cap of $2.76 billion, a P/E ratio of 931.50 and a beta of 1.66. The company has a fifty day moving average price of $44.37 and a two-hundred day moving average price of $46.49. Vericel Co. has a 1-year low of $32.31 and a 1-year high of $57.81.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. The business had revenue of $57.91 million during the quarter, compared to analyst estimates of $55.32 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%. On average, research analysts forecast that Vericel Co. will post 0.13 EPS for the current fiscal year.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.